Long-term outcomes for newly-diagnosed multiple myeloma patients treated with pegylated liposomal doxorubicin and bortezomib: final results of CALGB (Alliance) 10301, a multicentre phase II study

Long-term outcomes and updated clinical efficacy and safety data were evaluated for newly-diagnosed multiple myeloma patients treated on a phase II study of bortezomib and pegylated liposomal doxorubicin (PegLD). Out of 61 patients, the overall response rate was 57% and the near-complete/complete re...

Full beskrivning

Sparad:
Bibliografiska uppgifter
I publikationen:Br J Haematol
Huvudupphovsmän: Voorhees, Peter M., Orlowski, Robert Z., Mulkey, Flora, Watson, Peter, Geyer, Susan, Sanford, Ben L., Bennett, Elizabeth, Chanan-Khan, Asher A., Bloomfield, Clara D., Larson, Richard A.
Materialtyp: Artigo
Språk:Inglês
Publicerad: 2015
Ämnen:
Article
Länkar:https://ncbi.nlm.nih.gov/pmc/articles/PMC5569902/
https://ncbi.nlm.nih.gov/pubmed/26202857
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/bjh.13592
Taggar: Lägg till en tagg
Inga taggar, Lägg till första taggen!

Liknande verk